10 Most Promising Mid-Cap Healthcare Stocks According to Hedge Funds

9. Tango Therapeutics Inc. (NASDAQ:TNGX)

Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds.

On May 15, the price target on Tango Therapeutics Inc. (NASDAQ:TNGX) was increased from $28 to $55 by Leerink. Following the company’s results for the first quarter, the firm maintained an Outperform rating on the stock. Leerink sees this as a rare buying opportunity ahead of a significant twofold event that is anticipated by year’s end.

The firm observed that the stock has been under pressure, perhaps due to a competition cut and a loss of two board members. After speaking with management, it is now more optimistic about the projected data announcement in pancreatic ductal adenocarcinoma for the combination of daraxonrasib and vopimetostat.

The company’s optimism seems to have contributed to the choice to concentrate on the first-line pancreatic ductal cancer potential in conjunction with RAS(ON) inhibitors rather than starting vital research analyzing vopimetostat monotherapy in second-line pancreatic ductal adenocarcinoma. This strategic change, in Leerink’s opinion, is a wise move because success in the initial line of therapy may render later lines of treatment less effective and less profitable.

On May 14, Wedbush increased the target price for Tango Therapeutics Inc. (NASDAQ:TNGX) from $19 to $33, while upholding an Outperform rating on the shares. The adjustments came after the company’s quarterly results, and now lead to a revised upside potential of almost 43%.

Wedbush noted recent evolving vopimetostat developments and financing activities. It has forecasted continued PRMT5i data updates and asset development during the course of 2026.

Tango Therapeutics Inc. (NASDAQ:TNGX) is a precision oncology company focusing on the discovery and development of drugs targeting defined patient populations with unaddressed clinical needs. It develops TNG462, TNG45, and PRMT5 inhibitors for the treatment of pancreatic, lung, and brain cancer, respectively. The company is currently engaged in the development of TNG260 to treat lung cancer.